Lymphoma | Topics

 
Matthew J. Matasar, MD, Discusses Unmet Needs in Relapsed Indolent Non-Hodgkin Lymphoma
April 14, 2021

The lymphoma expert discussed how the addition of copanlisib to rituximab may add another treatment option for patients with relapsed indolent B-cell lymphomas.

Lenalidomide Plus R-CHOP Did Not Improve PFS Compared With Placebo Plus R-CHOP for ABC-Type DLBCL
April 08, 2021

Even though the safety profile remained tolerable, treatment with lenalidomide plus R-CHOP did not improve progression-free survival compared with placebo plus R-CHOP for patients with activated B-cell-like subtype of DLBCL.

Umbralisib Activity, Safety in Indolent Lymphomas Demonstrated in Phase 2b Trial
April 06, 2021

Data that led to the approval of umbralisib in patients with indolent non-Hodgkin lymphoma— including follicular lymphoma and marginal zone lymphoma—indicates favorable activity of the therapy versus other available PI3K inhibitors.